Whitehawk Therapeutics, Inc. (WHWK)
NASDAQ: WHWK · Real-Time Price · USD
2.860
+0.080 (2.88%)
Jan 22, 2026, 2:49 PM EST - Market open
Whitehawk Therapeutics Employees
Whitehawk Therapeutics had 22 employees as of September 30, 2025. The number of employees decreased by 31 or -58.49% compared to the same quarter last year.
Employees
22
Change
-31
Growth
-58.49%
Revenue / Employee
$653,818
Profits / Employee
-$709,909
Market Cap
134.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 22 | -31 | -58.49% |
| Jun 30, 2025 | 21 | -49 | -70.00% |
| Mar 31, 2025 | 18 | -57 | -76.00% |
| Dec 31, 2024 | 40 | -49 | -55.06% |
| Sep 30, 2024 | 53 | -35 | -39.77% |
| Jun 30, 2024 | 70 | -19 | -21.35% |
| Mar 31, 2024 | 75 | -5 | -6.25% |
| Dec 31, 2023 | 89 | 10 | 12.66% |
| Sep 30, 2023 | 88 | 12 | 15.79% |
| Jun 30, 2023 | 89 | 22 | 32.84% |
| Mar 31, 2023 | 80 | 26 | 48.15% |
| Dec 31, 2022 | 79 | 40 | 102.56% |
| Sep 30, 2022 | 76 | 55 | 261.90% |
| Jun 30, 2022 | 67 | 57 | 570.00% |
| Mar 31, 2022 | 54 | 44 | 440.00% |
| Dec 31, 2021 | 39 | 31 | 387.50% |
| Sep 30, 2021 | 21 | 13 | 162.50% |
| Mar 31, 2021 | 10 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Fate Therapeutics | 181 |
| Sutro Biopharma | 178 |
| Seres Therapeutics | 103 |
| Spero Therapeutics | 32 |
| Elicio Therapeutics | 32 |
| Oncolytics Biotech | 28 |
| Actuate Therapeutics | 10 |
WHWK News
- 14 days ago - Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 - PRNewsWire
- 7 weeks ago - Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer - PRNewsWire
- 2 months ago - Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 2 months ago - Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London - PRNewsWire
- 2 months ago - Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - PRNewsWire
- 3 months ago - Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC - PRNewsWire
- 3 months ago - Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research - Business Wire
- 4 months ago - Whitehawk Therapeutics, Inc. (WHWK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha